Moreover, the dual inhibition of EGFR/HER2 and IGF-1R signaling did produce stronger antitumor effects than either monotherapies in pancreatic cancer, ovarian cancer, colon cancer, etc. [30,31,32,33]. Here, ERBB2 is linked to ovarian carcinoma.